Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme

Chinese Medical Journal

Volumn 124, Issue 17, 2011, Pages 2611-2615

  Wang, Ming Dong ^a   Shi, Yan Fang ^a   Wang, Hong ^a   Wang, Jia Liang ^a   Ma, Wen Bin ^b   Wang, Ren Zhi ^b  

^a HEBEI UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Glioma; Isocitrate dehydrogenase 1; Virtual mutagenesis

Indexed keywords

CARBOXYL GROUP; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRIC ACID; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ALPHA CHAIN; AMINO ACID SUBSTITUTION; ARTICLE; BETA CHAIN; BINDING AFFINITY; BINDING SITE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; GENE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYDROGEN BOND; ISOCITRATE DEHYDROGENASE 1 GENE; MUTATIONAL ANALYSIS; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; VIRTUAL REALITY; WILD TYPE;

CATALYTIC DOMAIN; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; ISOCITRATES; MUTAGENESIS; MUTATION; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052528880     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.17.009     Document Type: Article

References (30)

1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
3. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
4. Henson JW. Treatment of glioblastoma multiforme: a new standard. Arch Neurol 2006; 63: 337-341.
5. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003; 138: 659-668.
6. Kraus JA, Felsberg J, Tonn JC, Reifenberger G, Pietsch T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 2002; 28: 325-333.
7. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009; 360: 813-815.
8. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
9. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
10. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1 (R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7-11.
11. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
12. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E, et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004; 279: 33946-33957.
13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000; 28: 235-242.
14. Hirashima A, Huang H. Homology modeling, agonist binding site identification, and docking in octopamine receptor of Periplaneta americana. Comput Biol Chem 2008; 32: 185-190.
15. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. Mol Graph Model 2003; 21: 289-307.
16. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 2011; 135: 35-45.
17. Srividhya J, Schnell S. Why substrate depletion has apparent first-order kinetics in enzymatic digestion. Comput Biol Chem 2006; 30: 209-214.
18. Hermann JC, Marti-Arbona R, Fedorov AA, Fedorov E, Almo SC, Shoichet BK, et al. Structure-based activity prediction for an enzyme of unknown function. Nature 2007; 448: 775-779.
19. Photaki I, Sakarellou-Daitsiotou M. Synthesis and catalytic properties of peptides containing amino-acids involved in the active centers of hydrolytic enzymes. J Chem Soc Perkin 1976; (6): 589-591.
20. Demetrius L. Role of enzyme-substrate flexibility in catalytic activity: an evolutionary perspective. J Theor Biol 1998; 194: 175-194.
21. Bretscher LE, Abel RL, Raines RT. A ribonuclease A variant with low catalytic activity but high cytotoxicity. J Biol Chem 2000; 275: 9893-9896.
22. Forneris F, Mttevi A. Enzymes without borders: mobilizing substrates, delivering products. Science 2008; 321: 213-216.
23. + pump. Comput Biol Chem 2009; 33: 14-21.
24. van Albada SB, Ten Wolde PR. Differential affinity and catalytic activity of CheZ in E. coli chemotaxis. PLoS Comput Biol 2009; 5: e1000378.
25. Rhoads RE, Udenfriend S. Decarboxylation of alpha-ketoglutarate coupled to collagen proline hydroxylase. Proc Natl Acad Sci U S A 1968; 60: 1473-1478.
26. 2+/alpha-ketoglutarate-dependent dioxygenase homologue. J Biol Chem 2000; 275: 32940-32949.
27. Ryle MJ, Koehntop KD, Liu A, Que L Jr, Hausinger RP. Interconversion of two oxidized forms of taurine/ alpha-ketoglutarate dioxygenase, a non-heme iron hydroxylase: evidence for bicarbonate binding. Proc Natl Acad Sci U S A 2003; 100: 3790-3795.
28. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71-103.
29. Hartong DT, Dange M, McGee TL, Berson EL, Dryja TP, Colman RF. Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle. Nat Genet 2008; 40: 1230-1234.
30. Encell LP, Landis DM, Loeb LA. Improving enzymes for cancer gene therapy. Nat Biotechnol 1999; 17: 143-147.